Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions
Effects of other drugs on Palazestrant
9 evidence topics · 6 sources
Strong CYP3A4 inhibitors and inducers in the phase 1/2 study
Medications with a known risk of QT prolongation
“Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proton pump inhibitors and antiemetics
“In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CYP3A4 metabolism and sensitivity to inhibition
Effect of ribociclib on palazestrant trough concentrations
Dose-normalized palazestrant trough concentrations with and without ribociclib
| Study | Dose-normalized steady-state trough, geometric mean (geometric SD); n | 90% confidence interval |
|---|---|---|
| OP-1250-001, single agent | “2.49 (48%); 172” | “[2.35, 2.64]” |
| OP-1250-003, combination with ribociclib | “3.35 (61%); 25” | “[2.77, 4.06]” |